Analyst Jeet Mukherjee from BTIG maintained a Buy rating on Arvinas Holding Company (ARVN – Research Report) and keeping the price target at $16.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Jeet Mukherjee has given his Buy rating due to a combination of factors surrounding Arvinas Holding Company’s recent developments. The VERITAC-2 trial results demonstrated that vepdegestrant, an ER degrader developed by Arvinas in partnership with Pfizer, showed a significant progression-free survival (PFS) improvement over fulvestrant in patients with ER+/HER2- breast cancer. This improvement is seen as clinically meaningful by key opinion leaders, positioning vepdegestrant as a competitive option in the market.
Additionally, vepdegestrant’s favorable tolerability profile, with lower rates of adverse events compared to other ER degraders like elacestrant and imlunestrant, could influence physician choice positively. The potential for commercial success is further bolstered by Pfizer’s strong presence in the breast cancer treatment space, which could aid in the adoption of vepdegestrant. The anticipated submission of a New Drug Application (NDA) in the second half of 2025 and a potential launch in 2026 also contribute to the positive outlook for Arvinas, supporting Mukherjee’s Buy rating.
In another report released yesterday, Piper Sandler also reiterated a Buy rating on the stock with a $14.00 price target.
Based on the recent corporate insider activity of 20 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ARVN in relation to earlier this year.